AstraZeneca’s first-half 2026 results show where that earnings growth is coming from. Total revenue increased 6% at constant ...

Focused on expanding access to innovation, deepening partnerships ...

AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and ...

The drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting targets ...

AstraZeneca (AZN) signed a drug-discovery deal with AI biotech insitro on Thursday, October 15, aimed at MASH, a serious liver disease, and cardiomyopathies, a group of heart-muscle diseases. The ...

AstraZeneca partners with insitro on an AI drug discovery deal worth up to $1.86 billion targeting fatty liver disease and ...

It was reported on September 25 that the U.S. FDA has accepted and granted Priority Review to AstraZeneca PLC (NYSE:AZN)’s supplemental Biologics License Application (sBLA) for IMFINZI (durvalumab) in ...

AstraZeneca (AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons why I ...

AstraZeneca agrees a $40m upfront deal with insitro to use AI in drug discovery for MASH and cardiomyopathies. Read more.

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant ...

AstraZeneca has some exciting things going on... AstraZeneca currently has three programs targeting diabetes and obesity care. During the ObesityWeek conference earlier this month, management provided ...

AstraZeneca Plc is collaborating with machine learning biotech Insitro Inc. in a deal worth as much as $1.86 billion intended ...